Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB052793 in Advanced Malignancies
NCT02265510Phase 2Terminated
- Sponsor
- Incyte
- Start
- Sep 2014
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of incb052793 in solid tumor, multiple myeloma (MM), acute myeloid leukemia (AML) and 5 more (3 arms), sponsored by Incyte. Primary endpoints: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) up to 3.4 years and Objective Response Rate in Hematological Malignancies up to 4.5 years. Started Sep 2014; status: terminated.
02
Drugs
incb052793
03
Conditions
solid tumormultiple myeloma (MM)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT02265510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265510.